Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Evotec SE

www.evotec.com

Latest From Evotec SE

Deal Watch: Genentech Inks New Collaborations With Skyhawk, Convelo

Skyhawk continues its recent spate of deal-making, using its SkyStar platform in a deal with Genentech, which also is looking into neurology with Convelo. AbbVie buys STING specialist Mavupharma, while Recordati pays Novartis $390m for Cushing’s products.

Deals Business Strategies

Finance Watch: Among Multiple Mega-Rounds, Revolution Raises $100m For RAS Programs

Private Company Edition: Revolution Medicines follows its Sanofi partnership and Warp Drive Bio buyout with a series C venture capital round to fund its RAS pathway inhibitors in cancer. The financing came during a boom in $100m-plus VC financings, including BioNTech's $325m series B.

Financing Business Strategies

New Antibiotic Class Is Aim Of Evotec R&D Pact With Nosopharm

Evotec and Nosopharm plan to develop and then test in humans the first novel antibiotic class for fighting Gram-negative Enterobacteriaceae infections in 40 years

Deals Platform Technologies

Evotec DNA Damage Response Spin-Out Aims For First IND-Ready Drug In 2022

Evotec’s chief science officer tells Scrip the German biotech is putting its cancer therapeutic program focused on DNA damage response into a new spin-off that aims to have an IND-ready drug in 2022.

Companies Cancer
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register